WNT6, a ligand and activator of the canonical WNT/β‐catenin pathway, was recently described to be overexpressed in GBM, having been associated with patients’ poor prognosis in multiple independent clinical cohorts (Gonçalves et al., 2018). Here, WNT6 is linked to glioblastoma.